Prostate cancer: 11. Alternative approaches and the future of treatment

CMAJ. Canadian Medical Association Journal

Volumn 160, Issue 4, 1999, Pages 528-534

  Trachtenberg, John ^a,c   Crook, Juanita ^a   Tannock, Ian F ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIANDROGEN; GONADORELIN AGONIST; GROWTH FACTOR RECEPTOR;

AGED; ALTERNATIVE MEDICINE; APOPTOSIS; ARTICLE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOLOGY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CASE REPORT; CELL DIFFERENTIATION; CLINICAL TRIAL; FAMILIAL CANCER; FUTUROLOGY; GENE THERAPY; HUMAN; LIFE EXPECTANCY; MALE; META ANALYSIS; PROSTATE CANCER; SURGICAL TECHNIQUE;

EID: 0033596734     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Goldenberg SL, Ramsey EW, Jewett MAS. Prostate cancer: 6. Surgical treatment of localized disease. CMAJ 1998; 159(10):1265-71.
2. Corral D, Pisters L, von Eschenbach A. Treatment options for localized prostate cancer following radiation therapy. Urol Clin North Am 1996;23(4):677-84.
3. Cespedes DR, Pisters LL, von Eschenbach AC, McGuire EJ. Long-term follow up of incontinence and obstruction after salvage cryosurgical ablation of the prostate: Results in 143 patients. J Urol 1997;157:237-40.
4. Gelet A, Dubernard JM, Cathignol D, Abdelrahim AF, Pangaud C, Souchon R, et al. Treatment of prostate cancer with transrectal focussed ultrasound: Early clinical experience. Eur Urol 1996;29:174-83.
5. Gelet A, Dubernard JM, Cathignol D, Blanc E, Souchon R, Pangaud C, et al. Preliminary results of the treatment of 44 patients with localized cancer of the prostate using transrectal focussed ultrasound. Prog Urol 1998;8:68-77.
6. Lancaster C, Toi A, Trachtenberg J. Interstitial microwave thermoablation for localized prostate cancer. Urology (in press).
7. Trachtenberg J, Kucharczyk W, Chen J, Murphy S, Lancaster C, Toi A, et al. Interstitial microwave thermoablation for localized prostate cancer after failed radiation therapy. In: Bodmer W, editor. New Perspectives in Prostate Cancer. 2nd Ed. Oxford: Isis Medical Media; 1999.
8. Kupelian P, Katcher J, Levin H, Zippe C, Soh J, Macklis R, et al. External beam radiotherapy vs radical prostatectomy for clinical stage T1-T2 prostate cancer: Therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason score. Cancer J Sci Am 1994;3(2):78-87.
9. Hanks GE, Lee WR, Hanlon AL, Hunt M, Kaplan E, Epstein BE, et al. Conformal technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ≥10 ng/mL. Int J Radiat Oncol Biol Phys 1996;35:861-8.
10. Warde P, Catton C, Gospodarowicz MK. Prostate cancer: 7. Radiation therapy for localized disease. CMAJ 1998;159(11):1381-8.
11. Ragde H, Blasko JC, Grimm PD, Kenny GM, Sylvester JE, Hoak DC, et al. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 1997;80:442-53.
12. Gleave ME, Bruchovsky N, Moore MJ, Venner P. Prostate cancer: 9. Treatment of advanced disease. CMAJ 1999;160(2):225-32.
13. Eisenberger M, Crawford ED, McLeod D, Loehrer P, Wilding G, Blumenstein B. A comparison of bilateral orchiectomy with or without flutamide in stage D2 prostate cancer [abstract]. Proc Am Soc Clin Oncol 1997;16:2a.
14. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995;346:265-9.
15. Dowling AG, Tannock IF. Systemic treatment for prostate cancer. Cancer Treat Rev 1998;24:283-301.
16. Scher HI, Zhang ZF, Nanus D, Kelly WK. Hormone and antihormone withdrawal: Implications for the management of androgen-independent prostate cancer. Urology 1996;47:61-9.
17. Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm. J Clin Oncol 1997;15:382-8.
18. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Sponner AE, Ogata GK, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393-8.
19. Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996;2:277-85.
20. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, et al. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997;57:314-9.
21. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805-13.
22. Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994;31:33-40.
23. Iscoe NA, Bruera E, Choo RC. Prostate cancer: 10. Palliative care. CMAJ 1999;160(3):365-71.
24. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative endpoints. J Clin Oncol 1996;14:1756-64.
25. Cresswell SM, English PJ, Hall RR, Roberts JT, Marsh MM. Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Br J Urol 1995;76:360-5.